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Introduction:  Heart  failure  is  associated  with  high  rates  of  readmission  and  mortality,  and  there
is a  need  for  measures  to  improve  outcomes.  This  study  aims  to  assess  the  impact  of  the
implementation  of  a  protocol-based  follow-up  program  for  heart  failure  patients  on  readmission
and mortality  rates  and  quality  of  life.
Methods:  A  quasi-experimental  study  was  performed,  with  a  prospective  registry  of  50  con-
secutive patients  discharged  after  hospitalization  for  acute  heart  failure.  The  study  group  was
followed by  a  cardiologist  at  days  7-10  and  the  first,  third,  sixth  and  12th  month  after  dis-
charge, with  predefined  procedures.  The  control  group  consisted  of  patients  hospitalized  for
heart failure  prior  to  implementation  of  the  program  and  followed  on  a  routine  basis.
Results: No  significant  differences  were  observed  between  the  two  groups  regarding  mean  age
(67.1±11.2 vs.  65.8±13.4  years,  p=0.5),  NYHA  functional  class  (p=0.37),  or  median  left  ventric-
ular ejection  fraction  (27%  [19.8-35.3]  vs.  29%  [23.5-40];  p=0.23)  at  discharge.  Mean  follow-up
after discharge  was  similar  (11±5.3  vs.  10.9±5.5  months,  p=0.81).The protocol-based  follow-up  program  was  associated  with  a  significant  reduction  in  all-
cause readmission  (26%  vs.  60%,  p=0.003),  heart  failure  readmission  (16%  vs.  36%,  p=0.032),
and mortality  (4%  vs.  20%,  p=0.044).  In  the  study  group  there  was  a  significant  improvement  in
all quality  of  life  measures  (p<0.001).∗ Corresponding author.
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Conclusion:  A  protocol-based  follow-up  program  for  patients  with  heart  failure  led  to  a  signif-
icant reduction  in  readmission  and  mortality  rates,  and  was  associated  with  better  quality  of
life.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an









Programa  de  seguimento  protocolado  de  doentes  com  insuficiência  cardíaca:  impacto
no  prognóstico  e  na  qualidade  de  vida
Resumo
Introdução: Os  doentes  com  insuficiência  cardíaca  (IC)  apresentam  taxas  elevadas  de  reinter-
namento  e  mortalidade,  tornando  necessária  a  implementação  de  medidas  que  conduzam  à  sua
redução. Avaliou-se  o  impacto  da  implementação  de  um  programa  de  seguimento  estruturado
de doentes  com  IC  nas  taxas  de  reinternamento  e  mortalidade  e  na  qualidade  de  vida.
Métodos: Estudo  quasi-experimental,  de  registo  prospetivo,  que  incluiu  50  doentes  consec-
utivos com  alta  após  internamento  por  insuficiência  cardíaca  aguda.  Os  doentes  iniciaram
seguimento  protocolado  após  alta,  por  cardiologista,  com  consulta  aos  7-10  dias,  1,  3,  6  e  12
meses, com  procedimentos  pré-definidos.  O  grupo-controlo  foi  constituído  por  doentes  inter-
nados por  insuficiência  cardíaca  previamente  à  implementação  do  programa,  seguidos  após  a
alta em  consultas  de  rotina.
Resultados:  Não  houve  diferenças  entre  ambos  os  grupos  no  respeitante  à  idade  média
(67,1±11,2 versus  65,8±13,4  anos;  p=0,5),  classe  funcional  da  NYHA  (p=0,37)  e  mediana  da
fração de  ejeção  do  ventrículo  esquerdo  [27%  (19,8-35,3)  versus  29%  (23,5-40);  p=0,23]  à  data
da alta;  o  tempo  de  seguimento  médio  foi  idêntico  (11±5,3  versus  10,9±5,5  meses;  p=0,81).
O seguimento  protocolado  associou-se  a  redução  significativa  das  taxas  de  reinternamento  por
qualquer causa  (26%  versus  60%,  p=0,003),  reinternamento  por  insuficiência  cardíaca  (16%  versus
36%, p=0,032)  e  mortalidade  total  (4%  versus  20%,  p=0,044).  No  grupo  em  estudo  verificou-se
melhoria  significativa  em  todos  os  parâmetros  de  qualidade  de  vida  (p<0,001).
Conclusão:  Um  programa  de  seguimento  protocolado  de  doentes  com  insuficiência  cardíaca  per-
mitiu redução  significativa  nas  taxas  de  reinternamento  e  mortalidade  e  associou-se  a  melhoria
da qualidade  de  vida.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um


































eart  failure  (HF)  is  an  important  public  health  problem  due
o  its  high  prevalence  and  impact  on  patients’  quality  of  life
nd  survival.1--11
In  Europe  and  the  USA,  the  estimated  prevalence  of  HF
s  1-2%  in  adults,1 and  a  10-15%  increase  in  the  number  of
ffected  individuals  is  projected  for  the  next  10-15  years,
eflecting  the  aging  of  the  population  (mainly  due  to  gen-
ral  improvements  in  health  care),  the  impact  of  risk  factors
n  the  genesis  of  the  syndrome,  and  the  role  of  comorbidi-
ies,  particularly  in  the  elderly.2--4 In  Portugal,  the  estimated
revalence  of  HF  is  4.4%,  reaching  8%  in  the  seventh  decade
f  life,  a  higher  prevalence  than  the  European  average.4--6
Despite  the  therapeutic  advances  achieved  in  recent
ecades,  especially  with  respect  to  reductions  in  sudden
7ardiac  death, the  mortality  attributed  to  HF  remains
igh.8,9 This  is  especially  true  following  hospitalization  due
o  decompensated  HF,  when  reported  mortality  is  17-24%




The  importance  of  hospitalization  for  HF  is  due  not  only
o  the  associated  mortality,  but  also  to  the  high  readmission
ate,12 which  imposes  a  significant  economic  burden  on  the
ealth  system  --  80%  of  the  costs  related  to  the  syndrome2
-  and  poor  quality  of  life  for  patients  with  HF.
The  readmission  rate  is  particularly  high  in  the  vulnerable
hase  (the  first  months  after  discharge),  with  one-fourth  of
atients  being  readmitted  in  the  first  month  after  discharge
nd  two-thirds  in  the  following  year.10,13 The  transition  phase
pre-  and  post-discharge)  is  therefore  of  particular  impor-
ance  in  terms  of  care,  planning  and  follow-up,  since  one  of
he  main  factors  responsible  for  early  readmission  is  lack  of
oordination  of  care  after  hospital  discharge.6,14
Several  post-discharge  follow-up  strategies  have  been
roposed,  although  not  all  have  shown  a  significant  impact
n  outcomes.15--17 Structured  follow-up  programs  based  on
ospital  consultations  are  often  associated  with  a  reduction
n  readmissions  during  the  first  year  (relative  risk  reduction
RRR]  of  19-30%),15,16,18 and  also  in  the  risk  of  death.15--17







































Protocol-based  follow-up  program  for  heart  failure  patients
therefore  recommended  by  the  European  Society  of  Car-
diology  (ESC).19 However,  much  of  the  evidence  on  which
this  recommendation  is  based  derives  from  a  time  when
some  contemporary  therapies,  particularly  cardiac  resyn-
chronization  therapy  (CRT)  and  implantable  cardioverter
defibrillators  (ICD),  were  not  widely  available.15--17 There  is
also  no  evidence  on  the  impact  of  the  implementation  of
such  programs  in  Portugal.
The  objective  of  this  single-center  study  was  to  assess
the  results  of  implementing  a  structured  follow-up  program
for  HF  patients  on  readmission  and  mortality  rates  and  on
quality  of  life,  after  an  episode  of  hospitalization  due  to  the
syndrome.
Methods
Design  and  population
This  was  a  quasi-experimental  design  study  carried  out  in
a  single  center  (the  cardiology  department  of  Santa  Maria
University  Hospital,  Lisbon,  Portugal).
The  study  population  consisted  of  50  consecutive  patients
admitted  for  acute  heart  failure  (AHF),  defined  as  new-
onset  AHF  or  decompensated  chronic  heart  failure,  to  the
general  cardiology  ward  (index  hospitalization),  who  were
discharged  after  the  implementation  of  a  protocol-based
follow-up  program  (beginning  in  April  2016).  The  diagnosis  of
HF  was  established  according  to  the  ESC  guidelines,  through
the  identification  of  symptoms  and/or  signs  of  HF  caused  by
a  structural  and/or  functional  cardiac  abnormality,  resul-
ting  in  reduced  cardiac  output  and/or  elevated  intracardiac
pressures.19
The  control  group  consisted  of  patients  selected  from  a
cohort  hospitalized  for  AHF  in  the  same  cardiology  ward
immediately  before  the  beginning  of  the  program  (from
October  2014  to  April  2016).  Patients  from  both  cohorts
(study  group  and  control  group)  were  classified  according
to  New  York  Heart  Association  functional  class  (NYHA)  at
discharge  (NYHA  I  vs.  NYHA  II  vs.  NYHA  III  or  IV),  left  ven-
tricular  ejection  fraction  (LVEF)  (tertiles),  and  age  (tertiles).
For  each  of  the  patients  in  the  study  group  a  patient  from
the  control  cohort  with  similar  scores  in  each  of  the  three
variables  was  randomly  selected.
Demographic,  clinical,  laboratory,  echocardiographic,
electrocardiographic  and  therapeutic  data  regarding  the
index  hospitalization  and  the  follow-up  period  after  dis-
charge  were  collected  for  the  study  group  and  for  all
patients  who  constituted  the  control  cohort.  Quality  of  life
was  assessed  at  discharge  and  at  six-month  follow-up  using
the  validated  Portuguese  version  of  the  Kansas  City  Car-
diomyopathy  Questionnaire  (KCCQ).20
Interventions  differentiating  the  study  group
The  main  differentiating  intervention  in  the  protocol-based
follow-up  program  was  consultations  by  a  cardiologist  at
days  7-10  and  the  first,  third,  sixth  and  12th  month  after
discharge  (and  additionally,  whenever  considered  necessary)






a)  Clinical  assessment  aimed  at  identifying  signs  or  symp-
toms  of  HF  decompensation,  residual  congestion  or  low
cardiac  output;
b)  Laboratory  assessment,  including  monitoring  of  plasma
N-terminal  pro-brain  natriuretic  peptide  (NT-proBNP)
level,  end-organ  dysfunction,  and  development  of  com-
mon  comorbidities  in  HF  patients  (diabetes,  chronic
pulmonary  disease,  dyslipidemia,  thyroid  dysfunction,
anemia,  iron  deficiency)19;
c)  Electrocardiogram  at  every  visit,  and  transthoracic
echocardiogram  between  the  third  and  sixth  months  and
every  12  months  of  follow-up;  when  considered  nec-
essary,  cardiac  magnetic  resonance  imaging  study  was
requested;
d)  Assessment  of  adherence  and  tolerance  to  therapy;
e)  Individualized  titration  of  therapy  in  accordance  with
the  ESC  guidelines19;
f)  Patient  education  regarding  self-care,  lifestyle  modifi-
cations,  and  management  of  HF  decompensation.19
tudy  outcomes
he  primary  outcome  was  all-cause  readmission.  HF  read-
ission,  death  and  the  composite  endpoint  of  all-cause
eadmission  or  death  were  secondary  outcomes.
In  the  structured  follow-up  program  group,  changes  in
uality  of  life  parameters  was  also  considered  a  secondary
utcome.
Also,  in  the  study  group,  LVEF  change  was  assessed  in
he  subgroup  of  patients  with  LVEF  <50%,  and  the  prescrip-
ion  rate  of  neurohormonal  antagonists  and  changes  in  their
espective  doses  during  follow-up  was  assessed  in  the  sub-
roup  of  patients  with  HF  with  reduced  LVEF  (HFrEF)  (LVEF
40%).
tatistical  analysis
ssuming  that  the  estimated  annual  rate  of  all-cause
eadmission  would  be  65%  in  the  control  group  and  35%  in
he  study  group  (based  on  HF  populational  studies10,13 and
F  post-discharge  programs  studies,15 respectively),  it  was
stimated  that  42  patients  would  need  to  be  followed  in
ach  group  for  12  months  to  provide  the  study  with  a  power
f  80%  to  detect  a  significant  relative  reduction  in  the  risk
f  all-cause  readmission  in  the  follow-up  program  group,  at
n  overall  two-sided  alpha  level  of  0.05.
The  statistical  analysis  was  performed  using  IBM  SPSS®
tatistics  version  20  (Chicago,  IL,  USA).  Categorical  varia-
les  are  reported  as  absolute  number  and  percentage  and
ontinuous  variables  are  reported  as  mean  and  standard
eviation  or  median  and  interquartile  range.  The  impact  of
nclusion  in  the  structured  follow-up  program  on  readmission
nd  mortality  rates  was  assessed  using  Cox  regression  and
aplan-Meier  survival  analysis.  Wilcoxon’s  test  was  used  to
ssess  the  impact  of  the  follow-up  program  on  quality  of  life,
oses  of  neurohormonal  antagonists  and  LVEF.  Differences
etween  the  groups  regarding  demographic,  clinical  and
herapeutic  data  were  established  using  the  Mann-Whitney,
tudent’s  t,  chi-square,  one-way  ANOVA  and  Fisher’s  exact































he  study  was  approved  by  the  local  ethics  committee  and
y  the  national  Data  Protection  Authority.  Patient  confiden-
iality  was  ensured  through  anonymization  of  the  collected
ata.  All  study  procedures  were  carried  out  in  accordance
ith  the  ethical  principles  expressed  in  the  2013  revision  of
he  Declaration  of  Helsinki.21
esults
opulation  characteristics
he  first  patient  was  enrolled  in  the  protocol-based  follow-
p  program  in  April  2016  and  the  50th  patient  in  November
017.  The  mean  follow-up  was  11±5.3  months  in  the  study
roup  and  10.9±5.5  months  in  the  control  group  (p=0.81).
Patients’  demographic  and  clinical  characteristics  at  dis-




Table  1  Population  characteristics  at  discharge.
Program  group  (n
Age,  years  (mean  ±  SD)  67.1±11.2  
Male gender,  n  (%)  38  (76)  
NYHA functional  class,  n  (%)
I 15  (30)  
II 32  (64)  
III 3  (6)  
IV 0  (0)  
Median LVEF,  %  (IQR) 27  (19.8-35.3)
HFrEF, n  (%) 43  (86)
HFmrEF, n  (%) 6  (12)
HFpEF, n  (%)  1  (2)  
Etiology,  n  (%)  
DCM 28  (56)  
Ischemic CMP  14  (28)  
Valvular CMP  5  (10)  
Other 3  (6)  
Median NT-proBNP,  pg/ml  (IQR)  1746  (887-4011)  
New-onset AHF,  n  (%)  17  (34)  
Decompensated  CHF,  n  (%)  33  (66)  
Comorbidities,  n  (%)
Hypertension  35  (70)  
Diabetes 17  (34)  
Anemiaa 8  (16)  
CKDb 20  (40)
CPD 20  (40)  
Length of  stay,  days  (median  (IQR)  10  (6-14.5)  
a Hemoglobin <12 g/dl (women) and <13 g/dl (men).
b Estimated glomerular filtration rate <60 ml/min/1.73 m2 (calcula
formula).
AHF: acute heart failure; CHF: chronic heart failure; CKD: chronic 
disease; DCM: dilated cardiomyopathy; HFmrEF: heart failure with m
ejection fraction; HFrEF: heart failure with reduced ejection fraction
pro-brain natriuretic peptide; NYHA: New York Heart Association.J.R.  Agostinho  et  al.
The  mean  age  of  the  follow-up  program  group  was
7.1±11.2  years  and  38  patients  (76%)  were  male.  Most
atients  were  in  NYHA  I  (30%)  or  II  (64%)  at  discharge;  all
atients  were  in  NYHA  III  (52%)  or  IV  (48%)  on  admission
index  hospitalization).  The  median  LVEF  documented  at
ischarge  was  27%  (19.8-35.3),  and  43  (86%)  patients  had
FrEF.  There  were  no  significant  differences  between  the
wo  groups  regarding  age,  NYHA  or  LVEF.
The  most  frequent  HF  etiology  in  both  groups  was  idio-
athic  dilated  cardiomyopathy  (56%  vs.  40%),  followed  by
schemic  heart  disease  (28%  vs.  28%).  Overall,  70%  of  the
atients  had  a  history  of  hypertension,  making  it  the  most
ommon  comorbidity  in  both  groups.
Median  length  of  stay  and  median  plasma  NT-proBNP  at
ischarge  did  not  differ  significantly  between  groups.ortality  and  readmission  rates
ompared  to  patients  in  the  control  group,  those  included
n  the  structured  follow-up  program  showed  a  significant
=50) Control  group  (n=50) p
65.8±13.4  0.5
32  (64)  0.28




29  (23.5-40) 0.23








1314  (587-3005)  0.20
12  (24) 0.38
38  (76)
35  (70)  1
25  (50)  0.16
7  (14)  1
27  (54)  0.23
16  (32)  0.53
9  (5-17)  0.44
ted by the Chronic Kidney Disease Epidemiology Collaboration
kidney disease; CMP: cardiomyopathy; CPD: chronic pulmonary
id-range ejection fraction; HFpEF: heart failure with preserved
; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal



















higher  rate  of  prescription  of  angiotensin-converting  enzyme
inhibitors  (ACEIs)/angiotensin  receptor  blockers  (ARBs)  was
observed  in  patients  included  in  the  follow-up  program
group  compared  to  controls  (100%  vs.  85%,  p=0.01).  ThereFigure  1  Kaplan-Meier  survival  curves  for  all-cause  readmi
admission (D).
reduction  in  all-cause  readmissions  (26%  vs.  60%;  hazard
ratio  [HR]  0.38  [0.2-0.73];  p=0.003)  (Figure  1A).  The  RRR
was  56.7%  and  the  number  needed  to  treat  (NNT)  was  2.91.  A
similar  benefit  was  achieved  in  HF  readmission  (RRR:  64.4%;
NNT:  3.45)  (Figure  1B).  Eighteen  (36%)  patients  in  the  control
group  were  hospitalized  due  to  AHF.  Implementation  of  the
protocol-based  follow-up  program  led  to  an  HF  readmission
rate  of  16%  (eight  patients)  (HR  0.4  [0.17-0.92];  p=0.032).
Mortality  was  significantly  lower  in  patients  enrolled
in  the  follow-up  program  (4%  vs.  20%;  HR  0.21  [0.05-
0.96];  p=0.044).  The  RRR  was  80%  and  the  NNT  was  6.25
(Figure  1C).
During  follow-up  two  (4%)  patients  in  the  study  group
died,  one  due  to  right  ventricular  failure  in  the  immedi-
ate  postoperative  period  following  cardiac  surgery,  and  the
other  due  to  sudden  death.  The  latter  patient  underwent  ICD
implantation  during  the  index  hospitalization  and  sudden
death  occurred  in  the  first  week  after  hospital  discharge,
before  the  first  protocol-based  follow-up  visit.  Autopsy  was
not  performed  and  interrogation  of  the  ICD  showed  no  dys-
rhythmia  or  evidence  of  device  dysfunction.  In  the  control
group,  two  (4%)  patients  died  during  HF  hospitalization,  and
four  (8%)  during  hospitalization  due  to  other  causes.
The  secondary  outcome  of  death  or  all-cause  hospitaliza-
tion  was  significantly  less  frequent  in  the  follow-up  program
group  (28%  vs.  68%;  HR  0.36  [0.19-0.67];  p=0.001),  with  an
NNT  of  only  2.5  (Figure  1D). (A),  heart  failure  readmission  (B),  death  (C),  and  death  or
uality  of  life  and  functional  class
n  the  study  group,  a  significant  improvement  was  observed
n  all  KCCQ  domains,  especially  in  the  overall  summary
cores  for  symptoms  (67%  vs.  89%,  p<0.001)  and  quality  of
ife  (66%  vs.  80%,  p<0.001)  (Table  2).
Parallel  to  the  improvement  in  the  KCCQ  symptoms
omain  reported  by  the  patients,  there  was  a  significant
mprovement  in  NYHA  class  documented  by  the  cardiolo-
ist  in  the  last  follow-up  visit  compared  to  NYHA  class  at
ischarge.  In  the  last  clinical  assessment  performed  most
atients  were  in  NYHA  I (64%  vs.  30%,  p<0.001)  (Figure  2).
herapy  with  neurohormonal  antagonists
s  stated  above,  the  majority  of  patients  in  both  groups
resented  HFrEF.  Table  3  describes  ongoing  therapy  (neu-
ohormonal  antagonists  and  cardiac  devices)  at  the  time  of
he  last  clinical  assessment.
The  rate  of  prescription  of  beta-blockers,  mineralocor-
icoid  receptor  antagonists  (MRAs)  and  ivabradine  did  not
iffer  between  the  two  groups.  However,  a  significantly
760  J.R.  Agostinho  et  al.
Table  2  Quality  of  life  in  the  study  group  as  assessed  by  the  Kansas  City  Cardiomyopathy  Questionnaire  (validated  Portuguese
version).
Baseline  assessmenta (n=50)  Six-month  follow-up  assessment  (n=44)  p
Symptoms
Physical  limitation  66  (43-77)  80  (72-90)  <0.001
Frequency 69  (39-89)  92  (73-100)  <0.001
Severity 64  (49-83) 89  (72-94) <0.001
Recent change 75  (50-83) 83  (67-100) 0.001
Subtotal  67  (40-85) 89  (76-96) <0.001
Global quality  of  life
Self-efficacy  75  (50-90)  90  (75-95)  <0.001
Quality of  life  60  (40-75)  77  (67-87)  <0.001
Social function  60  (37-85)  90  (60-100)  <0.001
Subtotal 66  (49-77)  80  (70-89)  <0.001
Total 68  (49-81)  84  (72-91)  <0.001
a Baseline assessment was performed at hospital discharge.
































to  the  latest  published  report  of  the  National  Program  forFigure  2  Changes  in  New  York  Heart  Assoc
ere  no  significant  differences  regarding  CRT  or  ICD  implan-
ation  rates  (Table  3).
Considering  the  whole  population,  there  were  no  signif-
cant  differences  in  diuretic  therapy  prescription  between
roups  (44  vs.  47  patients,  p=NS).  All  these  patients  were
edicated  with  loop  diuretics;  four  patients  in  the  follow-
p  program  group  and  six  patients  in  the  control  group  were
nder  an  association  of  a  loop  plus  a  thiazide  diuretic  (p=NS).
There  were  no  differences  in  myocardial  revasculariza-
ion  procedures,  either  percutaneous  angioplasty  (6%  vs.
%,  p=NS),  or  coronary  artery  bypass  graft  surgery  (2%  in
oth  groups,  p=NS).  Rates  of  aortic  (6%  vs.  8%,  p=NS)  and
itral  (6%  vs.  4%,  p=NS)  valve  interventions  (percutaneous
r  surgical)  were  also  similar  in  both  groups.
In  the  study  group  there  was  an  effective  optimiza-
ion  of  treatment  during  follow-up,  including  up-titration
f  recommended  drugs.  Significant  increases  in  the  doses
f  ACEIs/ARBs  (p=0.001),  beta-blockers  (p<0.001)  and
RAs  (p<0.001)  (Figure  3A-C,  respectively)  were  observed




n  (NYHA)  functional  class  during  follow-up.
In  the  subgroup  of  patients  with  HFrEF  or  HF  with
id-range  ejection  fraction  enrolled  in  the  protocol-based
ollow-up  program  (n=49),  there  was  a significant  improve-
ent  in  LVEF  during  follow-up  (27%  [19.8-35.3]  vs.  39.5%
29.5-50];  p<0.001).
iscussion
he  impact  of  hospitalizations  on  the  natural  history  of  HF
s  illustrated  by  the  frequently  reported  increase  in  mortal-
ty  during  the  period  that  follows  a  hospital  admission  due
o  the  syndrome.  In  this  period,  not  only  does  the  mortality
isk  increase,  but  a  vicious  cycle  leading  to  further  hospi-
alizations  is  triggered.10,22 This  is  of  major  importance  at  a
ime  when,  despite  all  the  therapeutic  advances,  HF  read-
ission  rates  continue  to  increase.9,23 In  Portugal,  accordingerebro-Cardiovascular  Diseases,9 the  number  of  hospital
dmissions  due  to  HF  episodes  was  19  434  in  2015  (2365
eaths),  an  increase  of  4000  episodes  compared  to  2011
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Table  3  Pharmacological  therapy  and  cardiac  devices  at  last  clinical  assessment.
Program  group  (n=43)  Control  group  (n=40)  p
Pharmacological  therapy
Beta-blocker  41  (95.3)  35  (87.5)  0.25
ACEI/ARB 43  (100)a 34  (85)  0.01
MRA 34  (79.1)  29  (72.5)  0.61
Ivabradine 5  (11.6)  2  (5)  0.44
Cardiac devices
CRT-P  3  (7)  6  (15)  0.32
CRT-D 11  (25.6)  9  (22.5)  0.8 0.12
ICD 11  (25.6) 4  (10) 0.09
a This group includes three patients treated with sacubitril/valsartan.
Data are reported as total number and percentage. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker;
CRT-D: cardiac resynchronization therapy with cardioverter-defibrilla
implantable cardioverter-defibrillator; MRA: mineralocorticoid recepto
Figure  3  Changes  in  the  doses  of  angiotensin-converting
enzyme  inhibitors  (ACEIs)/angiotensin  receptor  blockers  (ARBs)
(A), beta-blockers  (B)  and  mineralocorticoid  receptor  antago-







































tor; CRT-P: cardiac resynchronization therapy-pacemaker; ICD:
r antagonist.
15  583  hospitalizations,  2046  deaths),  making  it  impera-
ive  to  establish  strategies  that  may  lead  to  a  reduction  in
he  (re)hospitalization  rate,  and  consequently  in  mortality,
n  these  patients.6
In  this  study  we  present  the  characteristics  and  results  of
 protocol-based  follow-up  program  conducted  at  the  car-
iology  department  of  a  European  tertiary  hospital.  Prior
o  the  implementation  of  the  program,  on  the  basis  of  the
requency  of  major  events  in  the  control  group,  readmission
60%)  and  mortality  (20%)  after  hospital  discharge  in  patients
dmitted  for  an  HF  episode  were  similar  to  or  even  higher
han  those  reported  in  the  literature.10,11,13 The  HF  read-
ission  rate  in  our  control  population  was  similar  to  that
eported  in  published  data  on  Portuguese  cohorts  (36%  vs.
0.5%),  although  mortality  was  lower  (20%  vs.  34.3%).24 How-
ver,  implementation  of  the  structured  follow-up  program
ed  to  a  marked  reduction  in  all-cause  readmission  (abso-
ute  risk  reduction  of  40%),  and  also  to  a  considerable  though
maller  reduction  in  readmissions  due  to  decompensated  HF
absolute  risk  reduction  of  20%).  Concomitantly  a  significant
eduction  in  mortality  was  obtained  (from  20%  to  4%).
The  benefit  of  including  patients  in  the  follow-up  program
s  evident  when  the  secondary  endpoint  (death  or  readmis-
ion)  is  analyzed,  as  the  reduction  of  major  events  resulted
n  an  NNT  of  2.5,  which  is,  interestingly,  a  better  result  than
hat  reported  for  conventional  HF  therapies.25--32
Unlike  various  other  follow-up  or  monitoring  strategies
esigned  to  reduce  hospitalizations  and  mortality  in  the  HF
opulation,  such  as  telemonitoring  or  follow-up  programs
ased  on  telephone  contacts,33,34 protocol-based  follow-
p  programs  have  demonstrated  consistent  benefits.  These
enefits  do,  however,  not  reach  the  magnitude  reported  in
his  study.15--17 One  possible  reason  for  this  difference  may
e  that  most  of  the  beneficial  evidence  from  these  follow-
p  programs  goes  back  to  a  time  when  some  of  the  current
F  treatment  options  were  not  yet  available.
Additionally,  the  magnitude  of  benefit  achieved  may
e  related  to  the  intrinsic  characteristics  of  our  protocol-
ased  follow-up  program.  At  first,  during  hospitalization  and
n  the  pre-discharge  period,  a  careful  management  plan
as  set  up  according  to  the  patients’  characteristics  and















































































































n  face-to-face  consultations  and  on  predefined  procedures
see  Methods)  with  demonstrated  benefits  in  event  reduc-
ion,  favoring  a  holistic  approach  based  on  international
uidelines.19
It  is  important  to  highlight  the  frequency  of  the  consul-
ations,  with  particular  emphasis  on  the  visits  at  days  7-10
nd  at  one  month  after  discharge.  Early  post-discharge  vis-
ts  have  important  benefits  for  reducing  readmission  and
ortality,  not  only  during  the  first  month  after  discharge,
ut  also  thereafter.18,22,35 This  is  related  to  the  impor-
ance  of  the  hospital-home  transition  and  to  the  problems
hat  patients  usually  face,  including  difficulties  in  manag-
ng  medication,  unfamiliarity  with  the  necessary  changes
n  lifestyle,  lack  of  knowledge  about  their  disease,  and
anagement  of  worsening  symptoms.  The  role  of  the  early
ost-discharge  consultations  focuses  on  helping  with  these
roblems  and,  when  necessary,  on  therapeutic  optimization.
At  each  visit,  the  presence  of  symptoms  or  signs
ndicative  of  decompensation  was  carefully  assessed  and
ppropriate  therapeutic  measures  were  taken.  This  may
ave  contributed  decisively  to  the  marked  reduction  in  HF
eadmission.  However,  it  should  be  noted  that  much  of  the
enefit  derived  from  this  program  was  seen  in  the  reduction
n  all-cause  readmissions.  To  accomplish  this,  it  was  crucial
o  pay  particular  attention  to  the  monitoring  and  mana-
ement  of  comorbidities,  which  have  a  significant  impact
n  HF  patients’  prognosis,  as  most  hospitalizations  in  this
opulation  are  for  non-cardiac  causes.23
It  is  also  worth  emphasizing  the  effect  of  the  program  on
he  up-titration  of  neurohormonal  antagonist  doses,  as  the
ast  majority  of  patients  with  HFrEF  were  treated  with  beta-
lockers  (95.3%),  ACEIs/ARBs  (100%),  and  MRAs  (79.1%),  and
n  many  patients  target  doses  were  achieved  (46.5%,  47.5%
nd  60.5%,  respectively).  The  frequency  of  hospital  visits
nd  assessment  of  therapeutic  tolerance  may  have  played  a
art  in  this  achievement.  However,  although  optimization  of
harmacologic  therapy  may  have  had  an  important  role  in
he  observed  marked  reduction  of  events  during  follow-up,
t  should  also  be  noted  that  the  number  of  patients  treated
ith  these  drugs  in  the  control  group  was  also  high,  even
igher  than  previously  reported  in  Portuguese  HF  cohorts.24
he  rate  of  CRT  and  ICD  implantation  was  similar  between
he  two  groups  and  similar  to  that  reported  in  European
ohorts.10 This  finding  supports  the  added  benefit  of  this
ollow-up  program  with  holistic  interventions  on  top  of  the
enefit  associated  with  medical  and  device  HF  therapies.
The  follow-up  program  was  also  associated  with  sig-
ificant  improvements  in  both  NYHA  functional  class  and
uality  of  life  and  symptoms  as  assessed  by  the  KCCQ.  The
cores  obtained  in  both  domains  at  discharge  were  similar
o  those  in  the  literature  (66%  and  67%  vs.  56%  and  63%,
espectively),36 whereas  at  the  sixth  month  of  follow-up
he  scores  reported  herein  were  significantly  higher  (80%
nd  89%,  respectively).  Particular  attention  should  be  given
o  the  ‘self-efficacy’  sub-domain,  which  assesses  patients’
erceived  ability  to  manage  their  own  symptoms.  The  pop-
lation  included  in  the  follow-up  program  had  a  relatively
igh  self-efficacy  score  (75%)  at  the  time  of  discharge,  which
ay  be  due  to  the  education  on  patient  self-care  provided
uring  hospital  stay.  Nevertheless,  a  significant  additional
mprovement  (90%)  was  observed  during  follow-up,  demon-
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nd  health-related  education  reinforcement  carried  out  at
ach  consultation.  This  may  also  have  accounted  for  the
eduction  in  major  adverse  events.
To  our  knowledge  this  is  the  first  study  reporting  the
fficacy  of  a protocol-based  follow-up  program  in  reducing
eadmission  and  mortality  in  a  Portuguese  population  with
F,  filling  an  apparent  evidence  gap6,37 and,  we  hope,  per-
aps  helping  to  encourage  the  development  of  this  type  of
rogram  in  other  hospital  centers.
imitations
he  data  reported  should  be  interpreted  in  the  light  of  cer-
ain  limitations,  particularly  the  fact  that  this  was  not  a
andomized  controlled  study  and  that  the  sample  size  was
mall  (the  first  50  patients  enrolled  and  followed  by  pro-
ocol).  Besides,  only  patients  admitted  to  the  cardiology
epartment  were  included,  which  naturally  entails  selec-
ion  bias,  resulting  in  a  population  with  a  higher  proportion
f  patients  with  HFrEF  and  younger  than  those  reported  in
tudies  that  included  patients  admitted  to  internal  medicine
epartments.24 Additionally,  cost-effectiveness  analysis  was
ot  performed,  so  it  is  not  possible  to  determine  whether
he  reduction  in  events  during  the  follow-up  period  was
ccompanied  by  a  reduction  in  costs  attributed  to  HF.  How-
ver,  as  significant  reductions  in  the  admission  rate  were
btained,  this  probably  translated  into  reductions  in  costs
elated  to  the  syndrome  and  to  associated  comorbidities.
inally,  the  study  only  included  patients  with  a  recent  admis-
ion  due  to  AHF,  so  it  is  not  possible  to  assess  the  impact  of
his  follow-up  program  on  stable  patients  with  chronic  HF
ut  with  no  previous  recent  HF-related  hospital  admissions.
s  reported,  most  adverse  events  in  HF  patients  occur  in
he  first  year  after  hospital  discharge.10,11,13 In  fact,  despite
he  small  number  of  patients  who  completed  more  than  12
onths  of  follow-up  in  our  population,  through  the  data
btained  from  the  Kaplan-Meier  survival  curves  (Figure  1A-
),  it  may  be  assumed  that  the  incidence  of  major  adverse
vents  during  the  second  year  of  follow-up  would  have  been
ow,  suggesting  a  reduced  benefit  of  this  type  of  program
n  stable  patients,  as  previously  suggested.38,39 However,  we
onsider  that  more  evidence  is  needed  in  order  to  estab-
ish  the  ideal  duration  of  this  type  of  program,  according  to
atients’  clinical  profile  and  disease  progression.
onclusions
espite  all  the  advances  achieved  in  the  treatment  of
atients  with  HF  --  including  drugs  designed  to  modify  prog-
osis,  cardiac  devices  and  management  of  comorbidities  --
orbidity  and  mortality  attributed  to  the  syndrome  remain
igh.  Structured  follow-up  programs  may  have  a  key  role  in
he  management  of  these  patients.
This  study  reports  the  results  of  the  implementation  of
uch  a program  in  the  cardiology  department  of  a  tertiary
ospital,  and  is  the  first  to  document  its  benefits  in  a  Por-
uguese  population  with  HF.  The  program  was  associated
ith  marked  reductions  in  HF  readmission,  all-cause  read-
ission  and  mortality,  and  with  significant  improvements  in
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The  results  support  the  need  for  investment  in  this  type
of  program  as  a  means  to  improve  the  prognosis  of  patients
with  HF,  and  consequently  to  reduce  the  burden  attributed
to  the  condition.
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